Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques.

Kobinger GP, Figueredo JM, Rowe T, Zhi Y, Gao G, Sanmiguel JC, Bell P, Wivel NA, Zitzow LA, Flieder DB, Hogan RJ, Wilson JM.

Vaccine. 2007 Jul 9;25(28):5220-31. Epub 2007 May 7.

PMID:
17559989
2.

Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.

See RH, Petric M, Lawrence DJ, Mok CP, Rowe T, Zitzow LA, Karunakaran KP, Voss TG, Brunham RC, Gauldie J, Finlay BB, Roper RL.

J Gen Virol. 2008 Sep;89(Pt 9):2136-46. doi: 10.1099/vir.0.2008/001891-0.

PMID:
18753223
3.

Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.

See RH, Zakhartchouk AN, Petric M, Lawrence DJ, Mok CP, Hogan RJ, Rowe T, Zitzow LA, Karunakaran KP, Hitt MM, Graham FL, Prevec L, Mahony JB, Sharon C, Auperin TC, Rini JM, Tingle AJ, Scheifele DW, Skowronski DM, Patrick DM, Voss TG, Babiuk LA, Gauldie J, Roper RL, Brunham RC, Finlay BB.

J Gen Virol. 2006 Mar;87(Pt 3):641-50.

PMID:
16476986
4.

Studies of SARS virus vaccines.

Zheng BJ, Du LY, Zhao GY, Lin YP, Sui HY, Chan C, Ma S, Guan Y, Yuen KY.

Hong Kong Med J. 2008 Aug;14 Suppl 4:39-43. Review.

5.

Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV.

Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, Yokochi S, Kase R, Sekiguchi S, Morita K, Hishima T, Suzuki H, Karamatsu K, Yasutomi Y, Shida H, Kidokoro M, Mizuno K, Matsushima K, Kohara M.

J Immunol. 2008 Nov 1;181(9):6337-48.

6.

Enhanced induction of SARS-CoV nucleocapsid protein-specific immune response using DNA vaccination followed by adenovirus boosting in BALB/c mice.

Chunling M, Kun Y, Jian X, Jian Q, Hua S, Minsheng Z.

Intervirology. 2006;49(5):307-18. Epub 2006 Jun 29.

PMID:
16809936
7.

Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus.

Ba L, Yi CE, Zhang L, Ho DD, Chen Z.

Appl Microbiol Biotechnol. 2007 Oct;76(5):1131-6. Epub 2007 Jun 21.

PMID:
17581748
8.

A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.

Schulze K, Staib C, Schätzl HM, Ebensen T, Erfle V, Guzman CA.

Vaccine. 2008 Dec 2;26(51):6678-84. doi: 10.1016/j.vaccine.2008.09.006.

PMID:
18805454
9.

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice.

Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ.

Nature. 2004 Apr 1;428(6982):561-4.

PMID:
15024391
10.

Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats.

Liu RY, Wu LZ, Huang BJ, Huang JL, Zhang YL, Ke ML, Wang JM, Tan WP, Zhang RH, Chen HK, Zeng YX, Huang W.

Virus Res. 2005 Sep;112(1-2):24-31.

PMID:
16022898
11.

Effects of a SARS-associated coronavirus vaccine in monkeys.

Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, Bellini WJ, Barratt-Boyes S, Gambotto A.

Lancet. 2003 Dec 6;362(9399):1895-6.

PMID:
14667748
12.

Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.

Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S, Zhou Y.

Vaccine. 2007 Apr 12;25(15):2832-8. Epub 2006 Oct 30.

PMID:
17092615
13.

Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice.

Zakhartchouk AN, Viswanathan S, Mahony JB, Gauldie J, Babiuk LA.

J Gen Virol. 2005 Jan;86(Pt 1):211-5.

PMID:
15604448
14.

Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model.

Cameron MJ, Kelvin AA, Leon AJ, Cameron CM, Ran L, Xu L, Chu YK, Danesh A, Fang Y, Li Q, Anderson A, Couch RC, Paquette SG, Fomukong NG, Kistner O, Lauchart M, Rowe T, Harrod KS, Jonsson CB, Kelvin DJ.

PLoS One. 2012;7(9):e45842. doi: 10.1371/journal.pone.0045842. Epub 2012 Sep 24.

15.

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets.

Czub M, Weingartl H, Czub S, He R, Cao J.

Vaccine. 2005 Mar 18;23(17-18):2273-9.

PMID:
15755610
16.

Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses.

Huang J, Ma R, Wu CY.

Vaccine. 2006 Jun 5;24(23):4905-13. Epub 2006 Apr 4.

PMID:
16621188
17.

A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro.

Wang X, Xu W, Tong D, Ni J, Gao H, Wang Y, Chu Y, Li P, Yang X, Xiong S.

Immunol Lett. 2008 Aug 15;119(1-2):71-7. doi: 10.1016/j.imlet.2008.04.005. Epub 2008 May 19.

PMID:
18533276
18.

Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses.

Huang J, Cao Y, Du J, Bu X, Ma R, Wu C.

Vaccine. 2007 Sep 28;25(39-40):6981-91. Epub 2007 Jul 16.

PMID:
17709158
20.

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.

Spruth M, Kistner O, Savidis-Dacho H, Hitter E, Crowe B, Gerencer M, Brühl P, Grillberger L, Reiter M, Tauer C, Mundt W, Barrett PN.

Vaccine. 2006 Jan 30;24(5):652-61. Epub 2005 Aug 26.

PMID:
16214268
Items per page

Supplemental Content

Write to the Help Desk